U.S. Markets closed

MetaStat, Inc. (MTST)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.870.00 (0.00%)
At close: 2:48PM EDT
People also watch
PSCOWEBBTIERFPMICRPB

MetaStat, Inc.

27 Drydock Avenue
2nd Floor
Boston, MA 02210
United States
617-531-6500
http://www.metastat.com

Sector
Industry
Full Time Employees6

Key Executives

NameTitlePayExercisedAge
Mr. Douglas A. Hamilton B.Sc., MBAPres, Chief Exec. Officer & Director260kN/A51
Mr. Daniel H. SchneidermanVP of Fin., Controller & Sec.165kN/A39
Mr. Frederick E. Pierce IIVP of Investor RelationsN/AN/AN/A
Dr. Michael J. Donovan Ph.D., M.D.Acting Chief Medical OfficerN/AN/AN/A
Dr. Heinrich Dreismann Ph.D.Diagnostic ConsultantN/AN/A62
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MetaStat, Inc., a biotechnology company, focuses on discovering and developing personalized therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel therapeutic product candidates that target the Mena protein isoform driver-based diagnostic biomarkers; companion tests to be used in combination with cancer drugs, which provide information for the safe and effective use of a corresponding drug or biological product; and diagnostic tests that predict the risk of future metastasis in cancer patients following initial treatment of their primary tumor. Its product candidates include MenaINV assay for use as both a companion diagnostic and prognostic diagnostic; MenaCalc assay, a prognostic diagnostic for patients with early stage invasive breast cancer; and MetaSite Breast assay, a tissue-based immunohistochemistry assay that identifies and quantifies the sites of metastatic process. The company is based in Boston, Massachusetts.

Corporate Governance

MetaStat, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.